Identification | Back Directory | [Name]
Necitumumab | [CAS]
906805-06-9 | [Synonyms]
Necitumumab IMC-11F8/LY301221 Necitumumab (anti-EGFR) Research Grade Necitumumab(DHB86901) |
Hazard Information | Back Directory | [Clinical Use]
IgG1 monoclonal antibody:
Treatment of locally advanced or metastatic
epidermal growth factor receptor (EGFR) expressing
squamous non-small cell lung cancer | [Drug interactions]
Potentially hazardous interactions with other drugs
Live vaccines: avoid concomitant use. | [Metabolism]
The elimination routes of necitumumab are only partially
documented, and involve degradation to peptides after
being internalised into its target cells, proteolysis within
the liver or the reticuloendothelial system, as well as
nonspecific endocytosis. |
|
Company Name: |
DC Chemicals
|
Tel: |
021-58447131 13564518121 |
Website: |
http://www.approvedhomemanagement.com/ShowSupplierProductsList927327/0.htm |
Company Name: |
Biolab Reagents
|
Tel: |
027-65279366 18108604862 |
Website: |
www.biolabreagent.com/ |
|